CN Patent

CN106146503A — 一种Idelalisib的制备方法

Assigned to Shanghai Institute of Pharmaceutical Industry · Expires 2016-11-23 · 9y expired

What this patent protects

本发明公开了一种新的Idelalisib制备方法，该方法包括1)6-氯-9-(四氢-2-吡喃基)-嘌呤和(S)-2-(1-氨基-丙基)-5-氟-3-苯基-3H-喹唑啉-4-酮发生亲核取代反应得到(S)-5-氟-3-苯基-2-{1-[(9-四氢-2H-吡喃-2-基)-9H-嘌呤-6-基氨基]丙基}-3H-喹唑啉-4-酮；2)将第一步产物在盐酸乙醇中脱保护得到Idelalisib。本发明方法收率远高于现有技术，且后处理简单，只需要萃取和重结晶即可得到纯的Idelalisib，适于工业化生产。

USPTO Abstract

本发明公开了一种新的Idelalisib制备方法，该方法包括1)6-氯-9-(四氢-2-吡喃基)-嘌呤和(S)-2-(1-氨基-丙基)-5-氟-3-苯基-3H-喹唑啉-4-酮发生亲核取代反应得到(S)-5-氟-3-苯基-2-{1-[(9-四氢-2H-吡喃-2-基)-9H-嘌呤-6-基氨基]丙基}-3H-喹唑啉-4-酮；2)将第一步产物在盐酸乙醇中脱保护得到Idelalisib。本发明方法收率远高于现有技术，且后处理简单，只需要萃取和重结晶即可得到纯的Idelalisib，适于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number: CN106146503A
Jurisdiction: CN
Classification: —
Expires: 2016-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Institute of Pharmaceutical Industry
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.